Nephros, Inc. (NEPH) Names Andy Astor President and CEO

Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells water purification products and pathogen detection systems to the medical and commercial markets, today announced that Andy Astor, currently the company’s Chief Operating Officer and Chief Financial Officer, has been named President and CEO, effective August 24, 2020. Mr. Astor was also elected to Nephros’s board of directors.

Daron Evans, Nephros’s current President and CEO, will remain with the company as a special advisor focused on the pathogen detection and dialysis businesses. Mr. Evans will also continue as CEO of Specialty Renal Products (“SRP”), a Nephros subsidiary. As part of the transition, Mr. Evans will step down from Nephros’s board of directors.

“I am very pleased to announce Andy’s promotion to President and CEO,” said Mr. Evans. “Since joining the company in 2017, Andy has been instrumental to our success in growing revenues four-fold. Driven by an intense focus on serving our customers and strategic partners, Andy has led the development of operational and financial systems, built strong relationships with the investor community, raised the capital we needed, spearheaded the acquisition of the Aether™ filter brand, driven high-talent recruitment, and built a strong team-based organization and culture.”

Mr. Evans continued, “Going forward, Andy and I will continue to partner closely to build on this foundation and to drive the success of both Nephros and SRP. Although I have decided to transition to a reduced time commitment for personal reasons, I have had the privilege to lead the company for over five years, and I remain fully committed to Nephros’ success.”

“We congratulate Andy on this promotion, and it is a pleasure to welcome him to the board of directors,” said Paul Mieyal of Wexford Capital and board member of Nephros. “Over the past three years, he has demonstrated a deep commitment to the company, along with the acumen required to lead Nephros from early-stage to commercial-stage and beyond.”

“It is an honor to be asked to lead this organization,” said Andy Astor. “We have built a strong growth platform for the future, including deep relationships with many of the country’s leading water quality professionals. With more than 1,100 active customer sites using Nephros products to protect people from waterborne pathogens with our filtration and detection solutions, I am very pleased to take on this leadership role as we continue the company’s momentum and progress.”

You May Also Be Interested In

• Renovaro Biosciences (RENB) Appoints Geert Kazemier as the Chairman of its Scientific Advisory Board
• Korro Bio (KRRO) Announces $70M Placement
• Arthur J. Gallagher (AJG) Acquires Fontenelle & Goodreau Insurance